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Introduction
Numerous clinical trials have demonstrated that statins 
eﬀ ectively lower low-density lipoprotein-cholesterol 
(LDL-C) and reduce cardiovascular (CV) risk in people 
with dyslipidemia and Metabolic syndrome (MetS) or 
type  2 diabetes (T2D) [1,2]. A recent individual patient 
meta-analysis of 14 randomized clinical trials, for example, 
showed that a 1.0  mmol/l (38.6  mg/dl) reduc tion in 
LDL-C was associated with a signiﬁ cant 21% proportional 
reduction in major vascular events in people with T2D 
(0.79, 0.72 to 0.86; P <0.0001) and that the reduction was 
similar in people without T2D (0.79, 0.76 to 0.82; 
P  <0.0001) [1]. Most international treatment guidelines 
recommend lowering LDL-C to <2.6 mmol/l (100 mg/dl) 
in patients with high CV risk and to <1.8 to 2.0 mmol/l 
(70 to 80  mg/dl) in those at very high CV risk such as 
T2D with associated risk factors and established CV 
disease [3-7]. Despite these guidelines, the second Lipid 
Treatment Assessment Project (LTAP-2) showed that the 
proportion of patients who failed to achieve their 
recommended LDL-C target ranged from 16 to 53% 
across nine countries. Possible reasons for this failure 
include underdiagnosis, poor choice of ﬁ rst-line therapy, 
inadequate starting doses/failure to uptitrate or use 
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additional therapy, and poor persistence with medica-
tions due to cost, adverse events and/or drug–drug 
interactions (DDIs) [8]. If LDL-C-target attainment rates 
are to be improved, these problems must be avoided. It is 
therefore important to tailor the choice of ﬁ rst-line lipid-
lowering agent according to a patient’s individual clinical 
proﬁ le and therapeutic need.
Although LDL-C-lowering is important for the 
reduction of CV risk, studies have shown that the risk of 
CV events in patients that fully attain their recommended 
LDL-C-target is only reduced by about one-third [9], 
leaving substantial residual risk. In addition to elevated 
levels of LDL-C, people with MetS and T2D often have 
other lipid-related risk factors, such as high levels of 
triglycerides, low levels of high-density lipoprotein-
cholesterol (HDL-C), and a preponderance of highly 
athero genic, small, dense low-density lipoprotein particles 
[10-12]. Th e optimal management of dyslipidemia in 
people with these conditions should therefore address 
each of these risk factors in addition to LDL-C. However, 
further studies are required to fully understand the 
therapeutic beneﬁ ts of the various lipid-lowering drugs 
for the reduction of residual risk and to better deﬁ ne 
nonlow-density lipoprotein treatment targets.
Pitavastatin
Pitavastatin is a relatively new member of the statin 
family. Pitavastatin was ﬁ rst introduced in Japan in 2003 
for the treatment of primary hyperlipidemia or mixed 
dyslipidemia and has since been licensed for use in 13 
countries worldwide, including the USA, Japan, China, 
Germany and Spain. Pitavastatin has recently been 
approved for use in 20 additional countries, including the 
UK, Australia, and France, and is pending approval in a 
further 12 countries. Compared with other statins, 
pitava statin has a unique structure that contributes to a 
number of pharmacological beneﬁ ts, including increased 
systemic bioavailability [13], a high level of oral absorp-
tion [14,15] and potent eﬀ ects on LDL-C and HDL-C 
[16-19]. Th is review will discuss the potential beneﬁ ts for 
pitavastatin in the treatment of patients with MetS or 
T2D, focusing on its beneﬁ cial eﬀ ects on the atherogenic 
lipid triad, its neutral eﬀ ects on glycemic control and its 
reduced potential for DDIs.
Pitavastatin reduces LDL-C in people with 
Metabolic syndrome or type 2 diabetes
Numerous clinical trials have shown that pitavastatin is 
well tolerated and beneﬁ cially modiﬁ es the lipid proﬁ le 
with a similar or greater eﬃ  cacy to equivalent doses of 
atorvastatin, rosuvastatin, simvastatin and pravastatin in a 
wide range of patient subgroups [20-30], including those 
with MetS or T2D [23,24,31]. For example, the 16-week, 
randomized head-to-head PATROL trial (n = 302) showed 
that pitavastatin 2 mg/day reduced median LDL-C levels 
by 41% in patients with risk factors for coronary artery 
disease and elevated LDL-C levels (≥3.63 mmol/l; 140 mg/
dl), an eﬀ ect that was noninferior to atorvastatin 10 mg/
day (44%) and rosuvastatin 2.5 mg/day (42%) [30].
Similarly, a pivotal phase III study in 857 European 
patients with hypercholesterolemia or mixed dyslipid-
emia showed that 12-week treatment with pitavastatin 
2 mg/day reduced LDL-C by 39.0% compared with 35.0% 
with simvastatin 20  mg/day (P  =  0.014), whereas 
reductions with pitavastatin 4  mg/day and simvastatin 
40 mg/day were 44.0% and 42.8%, respectively (P = NS) 
[21]. A second study in a similar population (n  =  821) 
reported that 12-week treatment with pitavastatin 2 mg/
day reduced LDL-C by 37.9% compared with 37.8% with 
atorvastatin 10  mg/day (P  =  NS) (44.6% and 43.5%, 
respectively, with pitavastatin 4 mg/day and atorvastatin 
20  mg/day; P  =  NS) [20]. Importantly, the majority of 
patients with hypercholesterolemia or mixed dyslipid-
emia achieved their recommended National Cholesterol 
Education Program ATP III [3] and European Athero-
sclerosis Society [5] LDL-C targets within 12  weeks of 
treatment [20,21,32].
Th e Japanese long-term prospective post-marketing 
surveillance LIVALO Eﬀ ectiveness and Safety (LIVES) 
Study (n = 20,279) [33] and the JAPAN-ACS study [27] – 
a prospective, randomized, open-label study in patients 
with hypercholesterolemia and acute coronary syndrome 
(ACS) (n  =  251)  – showed that the LDL-C-lowering 
eﬃ  cacy of pitavastatin was similar among patients with 
and without T2D (–27.3% vs. –29.7%, respectively, in the 
LIVES study, and –35.7% vs. 36.4% in the JAPAN-ACS 
study). Furthermore, a subgroup analysis of the 12-week, 
randomized, open-label CHIBA study (n  =  53) showed 
that the percentage reduction from baseline in LDL-C 
was signiﬁ cantly greater with pitavastatin than with 
atorvastatin in patients with MetS (45.8% vs. 39.1%; 
P = 0.0495) [23]. Th e CHIBA study was carried out in a 
relatively small population and results should therefore 
be treated with caution. However, the authors suggest 
that this diﬀ erence may be due to the relationship 
between statin eﬃ  cacy and obesity. Whereas the LDL-C-
lowering eﬃ  cacy of atorvastatin was attenuated by 
increased waist circumference, body weight and BMI, 
pitavastatin’s eﬃ  cacy was unaﬀ ected by obesity-related 
parameters. Together these results suggest that pita va-
statin might be useful for the reduction of LDL-C in 
people with MetS or T2D, many of whom are overweight 
or obese.
Pitavastatin increases HDL-C levels in people with 
Metabolic syndrome or type 2 diabetes
Patients with MetS or T2D typically have low levels of 
HDL-C in addition to high levels of LDL-C and 
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triglycerides [10,11]. A subanalysis of the J-LIT study 
showed that a 2.6 mmol/l (10 mg/dl) increase in HDL-C 
was associated with a 34.9% reduction in the risk of 
coronary events in patients with T2D [34]. Moreover, 
studies have shown that increasing HDL-C levels using 
statins can signiﬁ cantly reduce the progression of athero-
sclerosis and reduce CV and cerebrovascular risk in 
people with dyslipidemia irrespective of LDL-C levels 
[35-39].
Although most statins increase HDL-C levels to some 
extent, eﬃ  cacy varies from statin to statin and eﬀ ects are 
not always consistent between trials [39-41]. For example, 
the VOYAGER study  – a meta-analysis of data from 
32,258 high-risk individuals in 37 randomized clinical 
trials  – showed dose-dependent increases in HDL-C 
ranging from 5.5 to 7.9% with rosuvastatin 5 to 40  mg 
and from 4.2 to 5.3% with simvastatin 10 to 80  mg, 
whereas the increases observed with atorvastatin were 
inversely related to the dose, falling from 4.5% with 10 mg 
to 2.3% with 80 mg [40]. In contrast, pitavastatin-treated 
patients routinely experience clinically signiﬁ cant, repro-
ducible elevations in HDL-C [22,42-44].
In the pivotal phase III studies, 12-week treatment with 
pitavastatin 2 to 4 mg/day increased HDL-C levels by 4 to 
6%  – an eﬀ ect that was similar among patients treated 
with simvastatin and atorvastatin [20,21]. However, the 
longer-term (52 week) Eﬀ ects of Pitavastatin and Atorva-
statin on HDL-cholesterol Levels in Patients with Hyper-
LDL Cholesterolemia and Glucose Intolerance (PIAT) 
study showed that pitavastatin 2 mg/day was associated 
with signiﬁ cant increases in HDL-C compared with ator-
va statin 10  mg/day (8.2% vs. 2.9%; P  =  0.031), an eﬀ ect 
that was reﬂ ected by increasing levels of apolipoprotein 
A-1 (5.1% with pitavastatin vs. 0.6% with atorvastatin; 
P = 0.019) (Figure 1) [24].
In another long-term trial  – the 70-month retro spec-
tive, single-center, observational CIRCLE study – HDL-C 
levels were increased by 13.4% with pitavastatin com-
pared with only 7.0% with atorvastatin in patients with 
percutaneous coronary intervention (n = 743) (P = 0.029) 
[44]. Th ese data suggest that the high-density lipoprotein 
(HDL)-elevating eﬀ ect of pitavastatin might increase 
over time. Consistent with this observation, an extension 
of the pivotal phase III studies showed that pitavastatin-
mediated elevations in HDL levels ultimately increased 
from 4% to 6% after 12  weeks to 14.3% after 60  weeks 
[22].
As for other statins [39], the degree of pitavastatin’s 
HDL-C-elevating eﬃ  cacy appears to be related to serum 
concentrations of HDL-C at baseline. For example, the 
PATROL study showed that neither pitavastatin nor 
atorvastatin had a signiﬁ cant eﬀ ect on HDL-C levels in 
patients with hypercholesterolemia and high baseline 
levels of HDL-C (~1.55  mmol/l; 60  mg/dl) [30]. In 
contrast, the KISHIMEN study in 178 Japanese subjects 
with hypercholesterolemia (58% with T2D) demonstrated 
signiﬁ cant pitavastatin-mediated elevations in HDL-C 
after 6 months ranging from 5.9% in the general cohort to 
22.4% in patients with low baseline HDL-C (<1 mmol/l; 
40 mg/dl) [45]. Similarly, the increase in HDL-C achieved 
with pitavastatin in the CIRCLE study was 21.3% among 
patients with a low baseline HDL-C level (≤1.17 mmol/l; 
45 mg/dl) compared with 13.4% in the general population 
[44]. A subanalysis of the 2-year LIVES study showed 
that pitavastatin 1 to 4  mg/day signiﬁ cantly increased 
HDL-C levels by 5.9% in all subjects (n  =  631) and by 
24.6% (P  <0.0001) in those with a low baseline HDL-C 
(<1 mmol/l; 40 mg/dl) (n = 86) (Figure 2) [46]. Moreover, 
HDL-C levels rose by 15.8% after patients with persis-
tently low levels of HDL-C despite previous statin treat-
ment switched to pitavastatin [42]. Th is observation 
suggests that patients might beneﬁ t from pitavastatin 
therapy if HDL-C remains unacceptably low on other 
treatments.
Pitavastatin-mediated high-density lipoprotein 
elevation has the potential to reduce residual risk 
via a number of mechanisms
HDL particles are central to the reverse cholesterol trans-
port pathway, a process in which excess cholesterol is 
removed from peripheral cells and transported to the 
liver for excretion into bile [11]. Th e suggestion has 
therefore been made that elevations in HDL-C might 
slow the formation of atherosclerotic plaques and may 
reduce the residual CV risk by increasing the rate of 
Figure 1. Pitavastatin presents greater high-density lipoprotein-
elevating and apolipoprotein A-1-elevating effi  cacy than 
atorvastatin. Pitavastatin has more signifi cant high-density 
lipoprotein (HDL)-elevating and apolipoprotein (Apo) A-1-elevating 
effi  cacy than atorvastatin in patients with hypercholesterolemia 
and glucose intolerance (52-week PIAT study). Values are means. 
*P = 0.031, two-sample t test. ‡P = 0.019, two-sample t test. 
Adapted from [24].
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cholesterol eﬄ  ux from cells. A post hoc analysis of 
intravascular ultrasono graphy data from four prospective 
randomized clinical trials (n = 1455) showed that statin-
treated patients with angiographic CHD experienced 
≥5% reduction in the coronary atheroma volume when 
LDL-C levels were sub stantially decreased to <2.21 mmol/l 
(87.5 mg/dl) and HDL-C levels were increased by >7.5% 
[36]. However, a recent review of the literature suggests 
that, whilst the plaque volume change induced by a 1% 
reduction in LDL-C showed little diﬀ erence using 
diﬀ erent statins (ator va statin, pravastatin, pitavastatin, 
rosuvastatin, simva statin), pitavastatin delivered the 
greatest reduction in plaque volume per 1% increase in 
HDL-C (Figure  3) [37]. Pitavastatin probably therefore 
beneﬁ cially modiﬁ es HDL function as well as quantity.
In addition to their role in reverse cholesterol trans-
port, normal HDL particles can inhibit some of the 
atherogenic processes that occur in people with MetS 
and T2D, including increased oxidation [47-49], vascular 
inﬂ ammation [50,51], thrombosis [52], endothelial dys-
func tion [53], and reduced insulin sensitivity [54-56]. A 
12-week, open-label multicenter study performed among 
103 consecutive patients with hypercholesterolemia 
showed that patients with MetS (n = 69) had signiﬁ cantly 
higher mean levels of plasma high-sensitivity C-reactive 
protein and signiﬁ cantly lower mean levels of high-
molecular-weight adiponectin than their counterparts 
without MetS (n  =  34) [51]. In this study, a signiﬁ cant 
correlation was observed between baseline high-
molecular-weight adiponectin levels and HDL-C values 
in patients with MetS (r  =  0.318; P  =  0.01) but not in 
those without. Moreover, an eﬀ ectiveness analysis 
including 62 patients with MetS and 32 patients without 
showed that the level of high-sensitivity C-reactive 
protein was signiﬁ cantly decreased in MetS patients 
during pitavastatin treatment, whereas high-molecular-
weight adiponectin levels did not change. When patients 
were grouped according to their percentage change in 
HDL-C, signiﬁ cantly greater pitavastatin-mediated in-
creases in high-molecular-weight adiponectin were 
observed in patients with versus patients without HDL 
elevations ≥10% (P = 0.009) (Figure 4). Th is observation 
suggests that pitavastatin might slow the progression of 
coronary atheromas by modifying HDL-related eﬀ ects on 
inﬂ ammation and oxidation, both of which are common 
in people with MetS and T2D.
Pitavastatin has a neutral eff ect on glucose control
A number of clinical trials have highlighted a potential 
association between statin therapy and an increased risk 
of developing T2D [57-60]. For example, the Justiﬁcation 
for the Use of Statins in Primary Prevention: An 
Intervention Trial Evaluating Rosuvastatin (JUPITER) 
study (n = 17,802) showed a signiﬁ cant 3.0% versus 2.4% 
increase in incident T2D among healthy adults treated 
with rosuvastatin 20 mg/day versus placebo for 1.9 years 
(P  =  0.01) [61]. Similarly, a meta-analysis of 13 statin 
trials including 91,140 patients without T2D showed that 
statin therapy (atorvastatin 10  mg, pravastatin 40  mg, 
simvastatin 40 mg or rosuvastatin 20 mg) was associated 
with a 9% increased risk for T2D over 4  years (odds 
ratio = 1.09; 95% conﬁ dence interval = 1.02 to 1.17) [58].
Figure 2. Pitavastatin presents high-density lipoprotein-
cholesterol-elevating effi  cacy that increases with time. 
Pitavastatin has signifi cant high-density lipoprotein-cholesterol 
(HDL-C)-elevating effi  cacy – especially in patients with low baseline 
HDL-C – that continues to increase over time (LIVES HDL substudy). 
Values are mean ± standard deviation. ANOVA, analysis of variance. 
Adapted from [46]. Figure 3. Pitavastatin induced greater plaque volume reduction 
by high-density lipoprotein cholesterol unit increase. Compared 
with other statins, pitavastatin is associated with the greatest 
reduction in plaque volume per 1% increase in high-density 
lipoprotein-cholesterol (HDL-C) (KISHIMEN study). Adapted from [37].
Masana Cardiovascular Diabetology 2013, 12(Suppl 1):S2 
http://www.cardiab.com/supplements/12/S1/S2
Page 4 of 8
Th e mechanisms by which statins might cause this 
eﬀ ect are unclear. A recent study carried out in 27 
patients with well-controlled T2D suggests that the 
potential diabetogenic eﬀ ects of simvastatin and rosuva-
statin are not driven by a detrimental eﬀ ect on insulin 
sensitivity, but rather by a deterioration of insulin secre-
tion [62]. In this study, patients were randomly assigned 
to receive either rosuvastatin 20  mg/day or simvastatin 
20 mg/day for 6 months followed by the other treatment 
for a further 6  months. Both strategies were associated 
with a similar 0.8 to 0.9% increase in hemoglobin A1c 
levels after 12 months (P <0.001 vs. baseline for both) and 
similar trends in fasting plasma glucose levels. No 
changes in insulin sensitivity were detected throughout 
the study, whereas HOMAβ levels were signiﬁcantly 
decreased in both groups.
In contrast, the CAPITAIN study in 14 healthy male 
adults with well-deﬁ ned MetS showed that 6-month 
treatment with the highest clinically available dose of 
pitavastatin (4 mg/day) did not signiﬁ cantly change mean 
glucose-related or insulin-related parameters, including 
fasting plasma glucose, the Homeostasis Model Assess-
ment index, insulin levels, insulin/glucose ratios, or 
hemoglobin A1c levels, and showed that glycemic para-
meters were generally improved [63]. Consistent with 
these results, a subanalysis of LIVES study data showed a 
signiﬁ cant 0.28% decrease in hemoglobin A1c levels 
(P <0.001) among 308 patients with T2D after 2 years of 
pitavastatin treatment (Figure 5) [46]. Th ese data suggest 
that whereas some statins are associated with adverse 
eﬀ ects on glycemic control, pitavastatin has a neutral and 
possibly beneﬁ cial eﬀ ect that is likely to be especially 
useful in people with, or at risk of developing, T2D  – 
such as those with MetS. Deﬁ nitive results on the impact 
of pitavastatin on the development of T2D are expected 
from the Japan Prevention Trial of Diabetes by Pita-
vastatin in Patients with Impaired Glucose Tolerance 
(J-PREDICT) study (n ~1,240) in 2015 [64].
Pitavastatin has a low potential for drug–drug 
interactions
People with MetS or T2D usually require multiple 
therapies for a range of CV risk factors. A study of 
Figure 4. Pitavastatin increases high-molecular-weight adiponectin levels. In patients with Metabolic syndrome, the percentage change from 
baseline in high-molecular-weight (HMW) adiponectin levels is signifi cantly greater in pitavastatin-treated patients achieving ≥10% increase in 
high-density lipoprotein-cholesterol (HDL-C) levels (PREMIUM study). Adapted from [51].
Figure 5. Pitavastatin presents signifi cant reductions in 
hemoglobin A1c levels that continue over time. Pitavastatin is 
associated with signifi cant reductions in hemoglobin A1c (HbA1c) 
levels that continue to decrease over time (LIVES study). Values are 
mean ± standard deviation. ANOVA, analysis of variance. Adapted 
from [46].
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>950,000 patient records from two US databases showed 
that 83% of patients with dyslipidemia used a CYP3A4-
metabolized statin and that, of these, 25 to 30% also 
received a CYP3A4 inhibitor [65]. Th is suggests that 
patients treated with statins have a particularly high risk 
of developing DDIs, some of which may lead to drug 
discontinuations owing to adverse events. Th e best way 
to avoid this problem is to use a statin with a low 
potential for DDIs.
Whereas lovastatin, simvastatin and atorvastatin are 
metabolized mainly by CYP3A4 and ﬂ uvastatin and 
rosuvastatin are metabolized by CYP2C9, pitavastatin’s 
cyclopropyl group diverts the drug away from meta bo-
lism by CYP3A4 and allows only a small amount of 
clinically insigniﬁ cant metabolism by CYP2C9. Moreover, 
studies in human hepatic micro somes have shown that, 
whereas the lactone metabolites of other statins are 
rapidly eliminated by CYP isoenzymes, both pitavastatin 
acid and lactone undergo limited metabolism [66]. It is 
not therefore surprising that the incidence of muscle-
related adverse drug reactions identiﬁ ed during a post 
hoc analysis of the LIVES study was unaﬀ ected by the 
concomitant administration of pitavastatin with drugs 
known to inhibit a range of CYP isoenzymes [67]. Th ese 
ﬁ ndings suggest that the pharmacokinetic data from 
interaction studies [68,69] are predictive of clinical 
experience and that pitavastatin has a low potential for 
DDIs. To date, the use of pitavastatin is contraindicated 
only in patients treated with cyclosporin or lopinavir/
ritonavir combination therapy. Administration should be 
temporarily sus pended in patients receiving 
erythromycin or fusidic acid, however, and the dosage 
should be limited to 2  mg in people treated with 
rifampicin. As for other statins, pitavastatin should be 
used with caution in people treated with ﬁ brates or 
niacin.
Overall, studies demonstrate that statins are well 
tolerated and have similar eﬀ ects on LDL-C levels in 
people with and without MetS or T2D. Compared with 
other statins, however, pitavastatin has a unique structure 
that contributes to a number of pharmacological beneﬁ ts. 
Th ese include potent LDL-C-lowering eﬃ  cacy, clinically 
signiﬁ cant, reproducible elevations in HDL-C, a neutral 
or beneﬁ cial eﬀ ect on glycemic control and a reduced 
potential for DDIs. Pitavastatin is therefore likely to be a 
useful treatment option for people with MetS or T2D.
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